pegcetacoplan: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
pegcetacoplan: clinical details
Prescribing considerations
- Initiate under supervision of a clinician experienced in haematological or renal disease.
- Confirm vaccination against meningococcus, pneumococcus and Haemophilus influenzae type B; provide appropriate antibiotic prophylaxis if treatment cannot wait for vaccine protection.
- Vaccination does not eliminate infection risk; provide the patient information pack and safety card.
- Assess suitability and provide competency-based training before home administration.
- For licensed renal indications, use with a renin–angiotensin system inhibitor unless it is contraindicated or not tolerated.
- Avoid abrupt withdrawal in PNH and arrange close follow-up if treatment is stopped.
- The product contains sorbitol and is unsuitable for hereditary fructose intolerance.
Contraindications and cautions
- Hypersensitivity to pegcetacoplan or an excipient
- Unresolved infection caused by encapsulated bacteria
- Lack of required vaccination unless appropriate antibiotic prophylaxis is provided
Monitoring
- Clinical features of serious infection and hypersensitivity
- Haemolysis symptoms and lactate dehydrogenase in PNH, including after discontinuation
- Renal function because the long-term significance of polyethylene glycol accumulation is unknown
- Disease-specific renal markers, including kidney function and proteinuria, where relevant
- Blood counts and other laboratory abnormalities according to clinical status
- Avoid silica-based aPTT reagents because results may be falsely prolonged
Clinical pharmacology
Pegcetacoplan is a PEGylated peptide inhibitor that binds C3 and C3b upstream of C3b opsonisation and membrane-attack-complex formation. It therefore suppresses both extravascular and intravascular complement-mediated haemolysis and reduces complement activity within affected kidneys.
Formulation and product differences
- The selected product is a ready-to-use, preservative-free solution in a single-use vial for subcutaneous infusion.
- Administration requires a compatible syringe-system pump or on-body delivery system; the permitted sites differ by device.
- Store refrigerated in the original carton, protect from light and do not mix with other medicinal products.
pegcetacoplan preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 1080 mg
pegcetacoplan interactions
Formal medicine-interaction studies have not been performed, although laboratory data suggest a low potential for conventional drug interactions. The specialist team should still review all prescribed, non-prescribed and complementary products.
Silica-based coagulation assay reagents
Pegcetacoplan can cause a falsely prolonged aPTT result; laboratories should use an appropriate alternative method.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.